Company profile
Home - Optellum
The world's first AI-based early lung cancer decision support software
Financial period: 1 Jul 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
SH01 | Transaction MzUyOTQ5OTczM2FkaXF6a2N4
Published 30 Jun 2026 15:34
SH01 | Transaction MzUxNTM3NTQxNGFkaXF6a2N4
Published 10 Apr 2026 12:16
RESOLUTIONS | Transaction WUVZN0JLTU9hZGlxemtjeA | Paper/PDF filed
Published 27 Mar 2026 15:13
MA | Transaction MzUxMTUzNDczMmFkaXF6a2N4 | Paper/PDF filed
Published 27 Mar 2026 15:08
AP01 | Transaction MzUxMjk2NzAzMWFkaXF6a2N4
Published 27 Mar 2026 12:04
Last confirmation statement made up date
AA | Transaction MzQ1NTg4NTcxMWFkaXF6a2N4
Published 20 Feb 2025 09:54
Last accounts made up date
Company registered at Companies House
1 Jul 2020 to 31 Mar 2024
We have assembled a team from academia, industry, charity and the NHS to integrate data from diagnostic technologies in novel ways using artificial intelligence algorithms. This will enable the earlier diagnosis of lung cancer for increased patient survival and large time and cost savings to the NHS. Lung cancer is the biggest cause of cancer death in the...
1 Jan 2019 to 31 Mar 2023
"We have formed a consortium of collaborating hospitals and commercial companies with public and patient involvement and input from charities to enable us to work with the public and the NHS to best develop and test the use of Artificial Intelligence programmes to improve health care. We are working with university academics and NHS hospitals across the c...
1 Dec 2016 to 31 Mar 2017
Optellum’s vision is to enable earlier and more confident cancer diagnosis and treatment by using Artificial Intelligence (AI) and Deep Learning to unlock new insights in huge image databases. Our first product that will target early detection of lung cancer, the World’s most common and lethal cancer. The US market holds the biggest potential due to estab...
